<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Elutia Inc. — News on 6ix</title>
<link>https://6ix.com/company/elutia-inc</link>
<description>Latest news and press releases for Elutia Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 17 Mar 2026 12:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/elutia-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683562da78dffbe2df0ef01e.webp</url>
<title>Elutia Inc.</title>
<link>https://6ix.com/company/elutia-inc</link>
</image>
<item>
<title>Elutia to Present at Sidoti’s Small-Cap Virtual Investor Conference March 18-19</title>
<link>https://6ix.com/company/elutia-inc/news/elutia-to-present-at-sidotis-small-cap-virtual-investor-conference-march-18-19</link>
<guid isPermaLink="true">https://6ix.com/company/elutia-inc/news/elutia-to-present-at-sidotis-small-cap-virtual-investor-conference-march-18-19</guid>
<pubDate>Tue, 17 Mar 2026 12:00:00 GMT</pubDate>
<description>GAITHERSBURG, Md., March 17, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills, Chief Executive Officer, and Matt Ferguson, PhD, Chief Financial Officer, will present and host one-on-one meetings with investors at the Sidoti Small-Cap Virtual Investor Conference, taking place March 18–19, 2026. During the presentation, management will discuss how Elutia is working to address post</description>
</item>
<item>
<title>Elutia Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/elutia-inc/news/elutia-announces-grants-of-inducement-awards-under-nasdaq-listing-rule-5635c4-110</link>
<guid isPermaLink="true">https://6ix.com/company/elutia-inc/news/elutia-announces-grants-of-inducement-awards-under-nasdaq-listing-rule-5635c4-110</guid>
<pubDate>Fri, 13 Mar 2026 04:00:00 GMT</pubDate>
<description>GAITHERSBURG, Md., March 13, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix</description>
</item>
<item>
<title>Elutia Reports Fourth Quarter and Full Year 2025 Financial Results; Initiates NXT-41 Regulatory Process</title>
<link>https://6ix.com/company/elutia-inc/news/elutia-reports-fourth-quarter-and-full-year-2025-financial-results-initiates-nxt-41-regulatory-process-8</link>
<guid isPermaLink="true">https://6ix.com/company/elutia-inc/news/elutia-reports-fourth-quarter-and-full-year-2025-financial-results-initiates-nxt-41-regulatory-process-8</guid>
<pubDate>Wed, 11 Mar 2026 04:00:00 GMT</pubDate>
<description>– Base biologic matrix NXT-41 submitted to FDA; on track for anticipated FDA clearance in second half of 2026 and full NXT-41x clearance in 1H27 – – $44.4</description>
</item>
<item>
<title>Elutia Regains Compliance with Nasdaq Listing Requirements</title>
<link>https://6ix.com/company/elutia-inc/news/elutia-regains-compliance-with-nasdaq-listing-requirements-8</link>
<guid isPermaLink="true">https://6ix.com/company/elutia-inc/news/elutia-regains-compliance-with-nasdaq-listing-requirements-8</guid>
<pubDate>Wed, 04 Mar 2026 05:00:00 GMT</pubDate>
<description>GAITHERSBURG, Md., March 04, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix</description>
</item>
<item>
<title>Elutia Selects Pete Ligotti as CCO to Lead the Commercial Launch of NXT-41x and Transform Post-Mastectomy Care in the $1.5B U.S. Breast Surgery Market</title>
<link>https://6ix.com/company/elutia-inc/news/elutia-selects-pete-ligotti-as-cco-to-lead-the-commercial-launch-of-nxt-41x-and-transform-post-mastectomy-care-in-the-dollar15b-us-breast-surgery-market</link>
<guid isPermaLink="true">https://6ix.com/company/elutia-inc/news/elutia-selects-pete-ligotti-as-cco-to-lead-the-commercial-launch-of-nxt-41x-and-transform-post-mastectomy-care-in-the-dollar15b-us-breast-surgery-market</guid>
<pubDate>Mon, 02 Mar 2026 05:00:00 GMT</pubDate>
<description>GAITHERSBURG, Md., March 02, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix</description>
</item>
<item>
<title>Elutia to Report Fourth Quarter 2025 Financial Results on Wednesday, March 11, 2026</title>
<link>https://6ix.com/company/elutia-inc/news/elutia-to-report-fourth-quarter-2025-financial-results-on-wednesday-march-11-2026</link>
<guid isPermaLink="true">https://6ix.com/company/elutia-inc/news/elutia-to-report-fourth-quarter-2025-financial-results-on-wednesday-march-11-2026</guid>
<pubDate>Wed, 25 Feb 2026 21:05:00 GMT</pubDate>
<description>GAITHERSBURG, Md., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its fourth quarter 2025 financial results after market close on Wednesday, March 11, 2026. Members of the Company’s management team will host a conference call and webcast starting at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time on the same day. The conference call can be accessed using the following</description>
</item>
<item>
<title>Where Purpose Meets Performance: Elutia Earns 2026 Great Place to Work Certification™</title>
<link>https://6ix.com/company/elutia-inc/news/where-purpose-meets-performance-elutia-earns-2026-great-place-to-work-certificationtm</link>
<guid isPermaLink="true">https://6ix.com/company/elutia-inc/news/where-purpose-meets-performance-elutia-earns-2026-great-place-to-work-certificationtm</guid>
<pubDate>Wed, 18 Feb 2026 13:00:00 GMT</pubDate>
<description>GAITHERSBURG, Md., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that it has been Certified™ by Great Place to Work®, the leading organization that evaluates workplace culture through a standardized, anonymous employee survey methodology developed over 30 years of research. The certification recognizes organizations with high-trust workplace cultures, where sustained engagement and reten</description>
</item>
<item>
<title>Elutia Reports Preliminary Fourth Quarter 2025 Results, Strengthened Financial Position, and Upcoming NXT-41x Milestones</title>
<link>https://6ix.com/company/elutia-inc/news/elutia-reports-preliminary-fourth-quarter-130000380</link>
<guid isPermaLink="true">https://6ix.com/company/elutia-inc/news/elutia-reports-preliminary-fourth-quarter-130000380</guid>
<pubDate>Mon, 12 Jan 2026 13:00:00 GMT</pubDate>
<description>Fourth quarter revenue up 16% year-over-year, $26.9M of secured debt eliminated, and total cash and escrowed proceeds of $44.3M at year-end GAITHERSBURG, Md., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today provided a corporate update and outlined upcoming development milestones for NXT-41x, its next-generation antibiotic-eluting biomatrix program in plastic and reconstructive surgery. NXT-41x is El</description>
</item>
<item>
<title>Elutia to Present at Global BioInnovation Forum on NXT-41x Biomatrix Program for Plastic and Reconstructive Surgery</title>
<link>https://6ix.com/company/elutia-inc/news/elutia-present-global-bioinnovation-forum-130000223</link>
<guid isPermaLink="true">https://6ix.com/company/elutia-inc/news/elutia-present-global-bioinnovation-forum-130000223</guid>
<pubDate>Fri, 09 Jan 2026 13:00:00 GMT</pubDate>
<description>Company to present Tuesday, January 13th at 10:00 a.m. PT / 1:00 p.m. ET GAITHERSBURG, Md., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced its participation in the inaugural Global BioInnovation Forum, taking place virtually during the JP Morgan Healthcare Conference on January 13, 2026. Elutia will highlight progress in its NXT-41x program, a next-generation antibiotic-eluting biomatrix</description>
</item>
<item>
<title>Elutia Reports Third Quarter 2025 Financial Results; Closes $88 Million Sale of BioEnvelope Business to Boston Scientific Corporation; Funds NXT-41x Development</title>
<link>https://6ix.com/company/elutia-inc/news/elutia-reports-third-quarter-2025-210500131</link>
<guid isPermaLink="true">https://6ix.com/company/elutia-inc/news/elutia-reports-third-quarter-2025-210500131</guid>
<pubDate>Thu, 06 Nov 2025 21:05:00 GMT</pubDate>
<description>- Rapidly advancing NXT-41x to address significant unmet medical need for plastic and reconstructive surgery, which represents an estimated $1.5 billion U.S. market opportunity Conference call today at 5:00 p.m. ET / 2:00 p.m. PT GAITHERSBURG, Md., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today provided a business update and financial results for the third quarter of 2025. Business Highlights: BioE</description>
</item>
<item>
<title>Elutia to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025</title>
<link>https://6ix.com/company/elutia-inc/news/elutia-report-third-quarter-2025-200500082</link>
<guid isPermaLink="true">https://6ix.com/company/elutia-inc/news/elutia-report-third-quarter-2025-200500082</guid>
<pubDate>Thu, 23 Oct 2025 20:05:00 GMT</pubDate>
<description>GAITHERSBURG, Md., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its third quarter 2025 financial results after market close on Thursday, November 6, 2025. Members of the Company’s management team will host a conference call and webcast starting at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time on the same day. The conference call can be accessed using the following</description>
</item>
<item>
<title>Elutia to Present at the LD Micro Main Event XIX Conference on Tuesday, October 21</title>
<link>https://6ix.com/company/elutia-inc/news/elutia-present-ld-micro-main-200500681</link>
<guid isPermaLink="true">https://6ix.com/company/elutia-inc/news/elutia-present-ld-micro-main-200500681</guid>
<pubDate>Tue, 14 Oct 2025 20:05:00 GMT</pubDate>
<description>GAITHERSBURG, Md., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills, President and Chief Executive Officer, will present at the LD Micro Main Event XIX Conference in San Diego on Tuesday, October 21, 2025, at 1:00 p.m. PT (4:00 p.m. ET). LD Micro Main Event XIX ConferencePresentation Date: Tuesday, October 21, 2025Presentation Time: 1:00 p.m. PT (4:00 p.m. ET)Webcast: Click here Elutia</description>
</item>
<item>
<title>Elutia Appoints Accomplished MedTech Veteran Guido J. Neels to Board of Directors</title>
<link>https://6ix.com/company/elutia-inc/news/elutia-appoints-accomplished-medtech-veteran-120000840</link>
<guid isPermaLink="true">https://6ix.com/company/elutia-inc/news/elutia-appoints-accomplished-medtech-veteran-120000840</guid>
<pubDate>Fri, 10 Oct 2025 12:00:00 GMT</pubDate>
<description>Industry leader brings 40 years of executive and board experience across the global medical technology sector GAITHERSBURG, Md., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, announced the appointment of Guido J. Neels to the Company’s Board of Directors. Mr. Neels will also serve as a member of the audit committee of the Board. In conjunction with Mr. Neels’ appointment, W. Matthew Zuga and Maybelle Jo</description>
</item>
<item>
<title>Elutia Announces Closing of BioEnvelope Business Sale to Boston Scientific Corporation for $88 Million</title>
<link>https://6ix.com/company/elutia-inc/news/elutia-announces-closing-bioenvelope-business-124100959</link>
<guid isPermaLink="true">https://6ix.com/company/elutia-inc/news/elutia-announces-closing-bioenvelope-business-124100959</guid>
<pubDate>Wed, 01 Oct 2025 12:41:00 GMT</pubDate>
<description>- Strengthened balance sheet to fully fund development and launch of NXT-41 platform - - Biologics for breast reconstruction represents $1.5 billion U.S. total addressable market - GAITHERSBURG, Md., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced the closing of the sale of its BioEnvelope business, including the EluPro™ and CanGaroo® bioenvelopes, to Boston Scientific Corporation (NYSE: B</description>
</item>
<item>
<title>Elutia Announces Newly Published Clinical Data Demonstrating that Biologic Envelopes Support CIED Stabilization and Ease of Reoperation</title>
<link>https://6ix.com/company/elutia-inc/news/elutia-announces-newly-published-clinical-120000455</link>
<guid isPermaLink="true">https://6ix.com/company/elutia-inc/news/elutia-announces-newly-published-clinical-120000455</guid>
<pubDate>Tue, 16 Sep 2025 12:00:00 GMT</pubDate>
<description>- Findings highlight the potential of antibiotic-eluting bioenvelopes to transform cardiac implantable electronic device (CIED) pocket management - GAITHERSBURG, Md., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced the publication of clinical and preclinical data supporting the clinical utility of a biologic envelope that secures cardiac implantable electronic devices (CIEDs), promotes ti</description>
</item>
<item>
<title>Elutia Announces Sale of BioEnvelope Business to Boston Scientific Corporation for $88 Million</title>
<link>https://6ix.com/company/elutia-inc/news/elutia-announces-sale-bioenvelope-business-123000918</link>
<guid isPermaLink="true">https://6ix.com/company/elutia-inc/news/elutia-announces-sale-bioenvelope-business-123000918</guid>
<pubDate>Tue, 09 Sep 2025 12:30:00 GMT</pubDate>
<description>- Transaction affirms the strength of Elutia’s proprietary drug-eluting biologics platform and fully funds advancement of NXT-41 in breast reconstruction - - Company to provide update at the H.C. Wainwright 27th Annual Global Investment Conference on Wednesday, September 10 at 9:30 a.m. ET - GAITHERSBURG, Md., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced it has entered into a definitiv</description>
</item>
<item>
<title>Elutia Selected to Exhibit EluPro™ Antibiotic Eluting BioEnvelope at Vizient Innovative Technology Exchange</title>
<link>https://6ix.com/company/elutia-inc/news/elutia-selected-exhibit-elupro-antibiotic-120000424</link>
<guid isPermaLink="true">https://6ix.com/company/elutia-inc/news/elutia-selected-exhibit-elupro-antibiotic-120000424</guid>
<pubDate>Thu, 04 Sep 2025 12:00:00 GMT</pubDate>
<description>GAITHERSBURG, Md., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that it has been selected to exhibit the EluPro™ Antibiotic-Eluting BioEnvelope at the Vizient Innovative Technology Exchange (“Vizient”). Vizient®, the nation’s largest provider-driven healthcare performance improvement company, will hold the Innovative Technology Exchange on Wednesday, September 17, 2025 in Las Vegas. Th</description>
</item>
<item>
<title>Elutia to Participate in Upcoming Investor Conferences</title>
<link>https://6ix.com/company/elutia-inc/news/elutia-participate-upcoming-investor-conferences-120000927</link>
<guid isPermaLink="true">https://6ix.com/company/elutia-inc/news/elutia-participate-upcoming-investor-conferences-120000927</guid>
<pubDate>Wed, 27 Aug 2025 12:00:00 GMT</pubDate>
<description>GAITHERSBURG, Md., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills, President and Chief Executive Officer, and Matt Ferguson, Chief Financial Officer, will participate in the following upcoming investor conferences in New York: Cantor Global Healthcare ConferenceFormat: Fireside Chat and 1x1 MeetingsFireside Chat Date and Time: Thursday, September 4, 2025, 9:45 a.m. ETWebcast Link: Cli</description>
</item>
<item>
<title>Elutia Delivers Robust Growth on the Strength of EluPro™ Market Adoption</title>
<link>https://6ix.com/company/elutia-inc/news/elutia-delivers-robust-growth-strength-200500846</link>
<guid isPermaLink="true">https://6ix.com/company/elutia-inc/news/elutia-delivers-robust-growth-strength-200500846</guid>
<pubDate>Thu, 14 Aug 2025 20:05:00 GMT</pubDate>
<description>EluPro™ Q2 revenue up 49% sequentially; Elutia advances next-generation drug-eluting biomatrix for breast reconstruction Conference call today at 5:00 p.m. ET / 2:00 p.m. PT GAITHERSBURG, Md., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today provided a business update and financial results for the second quarter of 2025. Since full launch in January 2025, EluPro has rapidly established itself as the</description>
</item>
<item>
<title>Elutia to Report Second Quarter 2025 Financial Results on Thursday, August 14, 2025</title>
<link>https://6ix.com/company/elutia-inc/news/elutia-report-second-quarter-2025-200500953</link>
<guid isPermaLink="true">https://6ix.com/company/elutia-inc/news/elutia-report-second-quarter-2025-200500953</guid>
<pubDate>Thu, 31 Jul 2025 20:05:00 GMT</pubDate>
<description>GAITHERSBURG, Md., July 31, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its second quarter 2025 financial results after market close on Thursday, August 14, 2025. Members of the Company’s management team will host a conference call and webcast starting at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time on the same day. The conference call can be accessed using the following</description>
</item>
</channel>
</rss>